S&P 500   3,635.71 (+1.62%)
DOW   30,046.25 (+1.54%)
QQQ   294.37 (+1.37%)
AAPL   115.30 (+1.27%)
MSFT   212.88 (+1.32%)
FB   276.20 (+2.89%)
GOOGL   1,757.15 (+1.71%)
AMZN   3,121.03 (+0.73%)
TSLA   558.61 (+7.04%)
NVDA   520.35 (-1.00%)
BABA   277.94 (+2.90%)
CGC   26.80 (+8.41%)
GE   10.42 (+3.48%)
MU   63.47 (-1.11%)
AMD   85.18 (-0.15%)
T   29.24 (+2.17%)
NIO   53.70 (-3.03%)
F   9.39 (+5.98%)
ACB   9.03 (+25.77%)
NFLX   482.35 (+1.20%)
GILD   60.62 (+1.22%)
BA   218.67 (+3.38%)
DIS   151.16 (+3.55%)
S&P 500   3,635.71 (+1.62%)
DOW   30,046.25 (+1.54%)
QQQ   294.37 (+1.37%)
AAPL   115.30 (+1.27%)
MSFT   212.88 (+1.32%)
FB   276.20 (+2.89%)
GOOGL   1,757.15 (+1.71%)
AMZN   3,121.03 (+0.73%)
TSLA   558.61 (+7.04%)
NVDA   520.35 (-1.00%)
BABA   277.94 (+2.90%)
CGC   26.80 (+8.41%)
GE   10.42 (+3.48%)
MU   63.47 (-1.11%)
AMD   85.18 (-0.15%)
T   29.24 (+2.17%)
NIO   53.70 (-3.03%)
F   9.39 (+5.98%)
ACB   9.03 (+25.77%)
NFLX   482.35 (+1.20%)
GILD   60.62 (+1.22%)
BA   218.67 (+3.38%)
DIS   151.16 (+3.55%)
S&P 500   3,635.71 (+1.62%)
DOW   30,046.25 (+1.54%)
QQQ   294.37 (+1.37%)
AAPL   115.30 (+1.27%)
MSFT   212.88 (+1.32%)
FB   276.20 (+2.89%)
GOOGL   1,757.15 (+1.71%)
AMZN   3,121.03 (+0.73%)
TSLA   558.61 (+7.04%)
NVDA   520.35 (-1.00%)
BABA   277.94 (+2.90%)
CGC   26.80 (+8.41%)
GE   10.42 (+3.48%)
MU   63.47 (-1.11%)
AMD   85.18 (-0.15%)
T   29.24 (+2.17%)
NIO   53.70 (-3.03%)
F   9.39 (+5.98%)
ACB   9.03 (+25.77%)
NFLX   482.35 (+1.20%)
GILD   60.62 (+1.22%)
BA   218.67 (+3.38%)
DIS   151.16 (+3.55%)
S&P 500   3,635.71 (+1.62%)
DOW   30,046.25 (+1.54%)
QQQ   294.37 (+1.37%)
AAPL   115.30 (+1.27%)
MSFT   212.88 (+1.32%)
FB   276.20 (+2.89%)
GOOGL   1,757.15 (+1.71%)
AMZN   3,121.03 (+0.73%)
TSLA   558.61 (+7.04%)
NVDA   520.35 (-1.00%)
BABA   277.94 (+2.90%)
CGC   26.80 (+8.41%)
GE   10.42 (+3.48%)
MU   63.47 (-1.11%)
AMD   85.18 (-0.15%)
T   29.24 (+2.17%)
NIO   53.70 (-3.03%)
F   9.39 (+5.98%)
ACB   9.03 (+25.77%)
NFLX   482.35 (+1.20%)
GILD   60.62 (+1.22%)
BA   218.67 (+3.38%)
DIS   151.16 (+3.55%)
Log in
NYSE:RMD

ResMed Stock Forecast, Price & News

$206.27
-3.30 (-1.57 %)
(As of 11/24/2020 02:57 PM ET)
Add
Compare
Today's Range
$204.83
Now: $206.27
$211.00
50-Day Range
$167.50
MA: $193.18
$220.59
52-Week Range
$108.85
Now: $206.27
$224.24
Volume18,520 shs
Average Volume663,684 shs
Market Capitalization$29.89 billion
P/E Ratio48.31
Dividend Yield0.74%
Beta0.38
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Read More
ResMed logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 1.8Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP76115210
Phone858-836-5000
Employees7,770

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.96 billion
Cash Flow$6.95 per share
Book Value$17.26 per share

Profitability

Net Income$621.67 million

Miscellaneous

Market Cap$29.89 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$206.27
-3.30 (-1.57 %)
(As of 11/24/2020 02:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ResMed (NYSE:RMD) Frequently Asked Questions

How has ResMed's stock price been impacted by COVID-19 (Coronavirus)?

ResMed's stock was trading at $153.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RMD stock has increased by 33.3% and is now trading at $204.83.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ResMed?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for ResMed
.

What stocks does MarketBeat like better than ResMed?

Wall Street analysts have given ResMed a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ResMed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for ResMed
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) posted its quarterly earnings results on Thursday, October, 29th. The medical equipment provider reported $1.27 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.98 by $0.29. The medical equipment provider had revenue of $751.90 million for the quarter, compared to analyst estimates of $709.47 million. ResMed had a return on equity of 30.34% and a net margin of 21.02%. The business's revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.93 earnings per share.
View ResMed's earnings history
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, October 29th. Investors of record on Thursday, November 12th will be given a dividend of $0.39 per share on Thursday, December 17th. This represents a $1.56 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date is Tuesday, November 10th.
View ResMed's dividend history
.

What price target have analysts set for RMD?

10 brokerages have issued 1-year target prices for ResMed's shares. Their forecasts range from $165.00 to $210.00. On average, they expect ResMed's share price to reach $189.40 in the next twelve months. This suggests that the stock has a possible downside of 7.5%.
View analysts' price targets for ResMed
.

Who are some of ResMed's key competitors?

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), The Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

Who are ResMed's key executives?

ResMed's management team includes the following people:
  • Dr. Peter C. Farrell A.M., Ph.D., BE (Hons), ScD, AM, Founder & Non-Exec. Chairman (Age 78, Pay $431.8k)
  • Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 48, Pay $2.73M)
  • Mr. Robert A. Douglas, Pres & COO (Age 60, Pay $1.99M)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 53, Pay $907.65k)
  • Dr. James R. Hollingshead Ph.D., Pres of Sleep & Respiratory Care Bus. (Age 57, Pay $1.27M)
  • Mr. Raj Sodhi, Pres of Software as a Service Bus. (SaaS) (Age 47, Pay $1.04M)
  • Mr. Kaushik Ghoshal, Chief Technology Officer
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 61)
  • Ms. Constance C. Bienfait, Director of Investor Relations
  • Ms. Amy Wakeham, VP of Investor Relations & Corp. Communications

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.17%), WCM Investment Management LLC (6.00%), State Street Corp (4.55%), JPMorgan Chase & Co. (1.13%), Charles Schwab Investment Management Inc. (0.50%) and UBS Asset Management Americas Inc. (0.49%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Justin Leong, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed
.

Which institutional investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., State Street Corp, Gateway Investment Advisers LLC, Fifth Third Bancorp, First Trust Advisors LP, The Manufacturers Life Insurance Company, Candriam Luxembourg S.C.A., and LaFleur & Godfrey LLC. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Rajwant Sodhi, Richard Mchale, and Robert Andrew Douglas.
View insider buying and selling activity for ResMed
.

Which institutional investors are buying ResMed stock?

RMD stock was purchased by a variety of institutional investors in the last quarter, including State of Tennessee Treasury Department, JPMorgan Chase & Co., WCM Investment Management LLC, Arrowstreet Capital Limited Partnership, Great West Life Assurance Co. Can, Allianz Asset Management GmbH, AQR Capital Management LLC, and AMF Pensionsforsakring AB.
View insider buying and selling activity for ResMed
.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $204.83.

How big of a company is ResMed?

ResMed has a market capitalization of $29.68 billion and generates $2.96 billion in revenue each year. The medical equipment provider earns $621.67 million in net income (profit) each year or $4.76 on an earnings per share basis. ResMed employs 7,770 workers across the globe.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.